NBRV - Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the Jefferies London Healthcare Conference. The presentation will be available on-demand beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm ET. Management will host investor meetings on Thursday and Friday, November 18-19, 2021.
The presentation may be accessed by visiting the " Investors " section of the Company's website under the "Events and Presentations" tab at www.nabriva.com . A replay of the webcast will be available for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
CONTACTS:
For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com
For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027